Skip to main navigation
Skip to content
Sensei Biotherapeutics
Clinical-Stage Biotechnology
Sensei Biotherapeutics

Investor Relations

  • About
  • Pipeline
    • Overview
    • SNS-301
    • SNS-401
    • Vista
    • Presentations
  • Platform
    • Immunophage
    • Therapeutic cocktails
    • Phortress
    • Immunophage + Nanobodies
    • GMP Manufacturing
    • Publications
  • Our Leadership
    • Senior Leadership
    • Board Of Directors
    • Immuno Oncology Advisory Board
  • Careers
  • Investors and Media
    • News Releases
    • Events & Presentations
    • Corporate Governance
      • Governance Overview
      • Board of Directors
      • Management
      • Committee Composition
    • Financial Information
      • SEC Filings
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Shareholder Services
      • Investor FAQs
      • Email Alerts
      • RSS Feeds
      • Contact Us
Contact

Investor Relations

  • About
  • Pipeline
    • Overview
    • SNS-301
    • SNS-401
    • Vista
    • Presentations
  • Platform
    • Immunophage
    • Therapeutic cocktails
    • Phortress
    • Immunophage + Nanobodies
    • GMP Manufacturing
    • Publications
  • Our Leadership
    • Senior Leadership
    • Board Of Directors
    • Immuno Oncology Advisory Board
  • Careers
  • Investors and Media
    • News Releases
    • Events & Presentations
    • Corporate Governance
      • Governance Overview
      • Board of Directors
      • Management
      • Committee Composition
    • Financial Information
      • SEC Filings
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Shareholder Services
      • Investor FAQs
      • Email Alerts
      • RSS Feeds
      • Contact Us

Email Alerts

Required fields denoted by an asterisk ().
Alert type

Investor Tools

  • Email Alerts
  • Investor FAQs
  • RSS Feeds
  • Contact Us
About

We are a biopharmaceutical company engaged in the discovery, development and delivery of next generation immunotherapies with an initial focus on treatments for cancer. We have developed two unique approaches – our ImmunoPhage™ platform and our monoclonal antibody and nanobody platform. Our proprietary ImmunoPhage™️ platform is a powerful, self-adjuvanted and highly differentiated immunotherapy approach that is designed to utilize bacteriophage to induce a robust, focused and coordinated innate and adaptive immune response. Using the ImmunoPhage platform, we are developing a library of ImmunoPhage, called Phortress™, to target multiple tumor-associated antigens. Our monoclonal antibody and nanobody platform is comprised of unique human monoclonal antibodies and alpaca derived nanobodies that are selectively active in the tumor microenvironment. Together, these platforms are designed to create a new class of personalized immuno-oncology medicines.

Contact
Headquarters
1405 Research Blvd, Suite 125
Rockville, MD 20850
Phone No
phone-icon

+1.240.243.8000

 

Boston R&D Location
451 D Street, Suite 710
Boston, MA 02210
Email
email-icon

info@senseibio.com

 

© 2021 Sensei Biotherapeutics, Inc. All Rights Reserved.

Legal

  • Privacy Policy

Social Links

Go to Top